ARCH invests primarily in companies co-founded by scientists and entrepreneurs, concentrating on bringing to market innovations in life sciences. They enjoy special recognition as a leader in the successful commercialization of technologies developed at academic research institutions and national laboratories. ARCH has raised ten venture funds totaling over $3 billion and has invested in the venture capital rounds for more than 150 companies. ARCH investors include corporations, pension funds, endowment funds, financial institutions, and private investors.

ARCH Venture Partners

Biomatics Capital Partners is a Seattle-based healthcare and life sciences venture firm. Biomatics is a $200 million fund that focuses on early-stage investments, primarily in genomics and digital health. Co-founders and General Partners Dr. Boris Nikolic and Julie Sunderland have invested together in emerging technology, health care, and life science ventures since 2010, leveraging their deep technical knowledge and partnering expertise with an established network of leading academics, pharma executives and venture capital firms.

Biomatics Capital Partners

Berggruen Holdings is an investment firm takes a long-term, value-oriented, often contrarian view. It prefers to build organically and through acquisitions, partnering with management, as opposed to quick, opportunistic exits. Depending on the opportunity and asset class, Berggruen Holdings is prepared to make relatively small investments as well as equity commitments of up to $100 million in any one transaction.

Berggruen Holdings

Alta Partners is a venture capital firm investing in the healthcare and life sciences sector. Their diverse and integrated team brings together a powerful depth of knowledge and experience, delivering tangible results for their companies and their investors.

Alta Partners

Heritage Provider Network (HPN) is a limited Knox-Keene licensed organization in California that provides affordable quality care to its members. Through innovative programs and services designed specifically for the managed care environment, HPN and its medical groups have been successful in delivering the goals it set out to achieve while establishing long-standing, favorable provider relationships.

Heritage Provider Network

Khosla Ventures invests in companies that are bold, early, and impactful. The firm was started in 2004 by Vinod Khosla, co-founder of Sun Microsystems, to provide venture assistance to entrepreneurs. Khosla Ventures invests in a range of areas including AI, climate, sustainability, enterprise, consumer, fintech, digital health, medtech and diagnostics, therapeutics, and frontier technology.

Khosla Ventures

Uprising™ is an independent digital creative studio based in Italy.

Uprising

Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company's strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that are developing transformative new modalities and platforms to meaningfully improve human health.

Alexandria Venture Investments

The JDRF T1D Fund (www.t1dfund.org) is a venture philanthropy fund exclusively devoted to finding and funding the best early-stage T1D commercial opportunities to accelerate the delivery of treatments, preventions, and cures to patients. It was created to solve a critical funding gap in the T1D drug and device development pipeline. Through partnerships with private capital, including venture capital, pharma and foundations, the T1D Fund anticipates that it will be able to attract substantially more private investment to the T1D field than occurs today. The T1D Fund will initially focus on artificial pancreas systems, metabolic control, beta cell replacement, prevention, and beta cell restoration therapies, with an exclusive priority on the best commercial opportunities. The T1D Fund will reinvest any realized gains into new investments to further its mission.

JDRF T1D Fund

E Squared Capital Management is a multi-strategy fund that invests in public and private companies.  Founded in 2009, our flexible approach and team of seasoned professionals has particular expertise investing in companies that will provide for superior risk-adjusted returns with low correlation to overall markets in a wide array of industries.    We achieve this objective by strategically investing in equity securities.  Our proprietary analysis uncovers companies that are undervalued when compared to our internally generated price targets.  We often invest in special events including restructurings, spin-offs, IPOs, secondary offerings, block trades, and registered direct offerings.  E Squared will seek to capture the relative value inherent in equity issues, taking a number of fundamental and trading factors into consideration.

E Squared Capital Management

Fan Ventures

Fresenius Medical Care is a provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 1.89 million individuals worldwide. It has a network of 2,716 dialysis clinics in North America, Europe, Latin America, Asia-Pacific, and Africa.  It offers specialty pharmacy and laboratory services and manufactures and distributes the most comprehensive line of dialysis equipment, disposable products, and renal pharmaceuticals. The company was founded in 1996 and is headquartered in Bad Homburg, Frankfurt.

Fresenius Medical Care

Wellington Partners is a venture capital firm that invests in technology and life sciences companies, focusing on Digital Media, Software, Electronics & Photonics, Resource Efficiency, and Biotech/Life Sciences. It is committed to providing outstanding entrepreneurs with the necessary resources to fund their strategies. We typically lead financing rounds ranging from € 0.5 million to € 20 million. Depending on the maturity of the company, its own commitment can go as high as € 15 million. Wellington was established in 1998 and has offices in Munich, London, and Zurich.

Wellington Partners

Leaps by Bayer invests in paradigm-shifting advances in the life sciences and specializes in the fields of biotechnology, agriculture, and scientific breakthrough. The firm's approach is making significant and sustained investments in disruptive biotechnologies that could have the greatest impact on humanity. It was founded in 2015 and headquartered in Leverkusen, Nordrhein-Westfalen.

Leaps by Bayer

Polaris Partners invests in healthcare and biotechnology companies. Their healthcare portfolio companies' care delivery models include digital health, consumer-centric businesses, patient-provider solutions, data science, and analytics. Their life sciences and biotechnology portfolio companies focus on molecules and platforms, therapeutics, and genomics.

Polaris Partners

Farallon Capital Management, L.L.C. is an American capital management firm that manages funds on behalf of institutions and individuals with significant capital. Based in San Francisco, the firm was founded by Thomas F. Steyer in March of 1986. As of September 2008, it has around 150 employees.  While it invests across the capital structure and in all asset classes, a large amount of its investments are in risk arbitrage, restructuring and recapitalization. Investments include public and private debt and equity securities, direct investments in private companies, and real estate. Farallon's real estate investments span the United States, Europe, Latin America and India.

Farallon Capital Management

Invus recognizes that every company is unique and that extraordinary business performance cannot be achieved by following a formulaic approach. Due to their unique structure, they have a great deal of flexibility in the types of companies and situations where they can get involved. They know that real transformation takes time and that it is never a straight line. They fully align their incentives with their partners and have the wherewithal and long-term commitment to see through any bumps along the way. They have been successfully empowering owner-managers since 1985. They have been reinvesting the same pool of money from the same group of European families (through their Artal investment vehicle) since their founding. Today they manage over $4 billion in an evergreen fund and work out of offices in New York, London, Paris and Hong Kong.

Invus

Osage University Partners is a venture capital firm focused on investing in startups that are commercializing university technologies. Osage partners with research universities to invest in their innovative startups shareing its investment profit with partner institutions. The firm invests in software, hardware, and life science companies at all stages of company development. To date, it has partnered with over 80 universities, including 36 of the top 50 U.S. institutions by research expenditures, and has invested in over 50 of their spinouts.

OUP (Osage University Partners)

As a venture capital company, HBM BioVentures is invested globally in some 40 mature emerging companies in the biotechnology/human medicine, diagnostics and medical technology sectors. The primary products of HBM BioVentures' portfolio companies are either at an advanced stage of development or already available on the market. The company focuses on unquoted emerging companies, with two-thirds are invested in private companies that offer high value creation potential. This has enabled HBM BioVentures to carve out a unique and distinctive market position. HBM BioVentures has a broad shareholder base and is listed on the SIX Swiss Exchange (ticker: HBMN).

HBM Healthcare Investments

Irving was founded in 2009 as a dedicated equity fund focused on disruptive technology and high growth opportunities and has since expanded into credit and private investments. The fund looks to form meaningful relationships with companies by offering its capital, expertise, and connections to promote growth and return on investment. Irving has been involved in several successful private exits and is a trusted advisor and LP in Venture Capital funds.

Irving Investors

LifeSci Venture Partners is an early-stage investment firm that invests in early-stage life sciences and healthcare companies. The firm provides companies in the life sciences industry with comprehensive solutions to communications and investor outreach. Their investment principals have broad-ranging life sciences experience including public and private investing, deal structuring, investment banking, equity capital markets, equity research, and bench research both basic science and applied.

LifeSci Venture Partners

Samsara Biocapital provides investment advisory services to help entrepreneurs turn their own ideas and visions into successful companies. Samsara BioCapital, as a results-driven organization, is always looking for ambitious and visionary partners with the drive and flexibility to take their company to the next level. Samsara BioCapital promotes biotech innovation and collaborates with inspiring companies as they develop important and innovative new therapies.

Samsara BioCapital

Altium Capital is a healthcare investment firm focusing on the development of stage public mid-and small-cap equities. It focuses on identifying opportunities to invest in growth companies in the healthcare industry. Founded in 2017 by Jacob Gottlieb, Altium Capital is headquartered in New York.

Altium Capital

Catalio Capital Management is a venture capital firm that invests in breakthrough biomedical technology companies. It was created by George Petrocheilos and Dr. Jacob Vogelstein in 2020.

Catalio Capital Management

SymBiosis LLC is a biotech-focused investment vehicle.

SymBiosis LLC

Monashee Investment Management is a hedge fund.

Monashee Investment Management

Lux Capital manages over $5 billion in assets focused on founding, seed, early-stage, and growth investments at the intersection of technology and the sciences. Lux takes an active role in helping entrepreneurs build successful businesses in high-growth sectors. Its investment team has built over 20 companies from scratch. Lux's investment strategy ensures portfolio companies are better connected, have a deeper insight, and command industry leadership faster than their competitors.

Lux Capital

DaVita is a provider of kidney care in the United States, delivering dialysis services to patients with chronic kidney failure and end stage renal disease. DaVita strives to improve patients’ quality of life by innovating clinical care, and by offering integrated treatment plans, personalized care teams and convenient health-management services. As of June 30, 2012, DaVita operated or provided administrative services at 1,884 outpatient dialysis centers located in the United States, serving approximately 149,000 patients. The company also operated 19 outpatient dialysis centers located in four countries outside the United States. DaVita supports numerous programs dedicated to creating positive, sustainable change in communities around the world. The company’s leadership development initiatives and social responsibility efforts have been recognized by Fortune, Modern Healthcare, Newsweek and WorldBlu.

DaVita

Parkwood is a dynamic and fast-growing private financial services company based in Cleveland, Ohio.

Parkwood

Natco Pharma is a manufacture and market affordable medicines that comply with global standards and to achieve market leadership in domestic as well as international markets.

Natco Pharma

Eisai Innovation, Inc. is a strategic investment organization aspiring to identify synergies between the scientific community and the Eisai network of companies.

Eisai Innovation

EGenesis

EGenesis is a biotechnology company developing solid organ and therapeutic cell transplantation to treat diseases. It offers gene editing and genome engineering platform to develop human-compatible organs, tissues, and cells, aiming to provide an alternative solution to the global organ shortage.

<div>eGenesis specializes in gene editing for organ transplantation purposes. It develops human compatible (HuCo) organs and cells by using organs of other species (especially pigs) in a procedure called xenotransplantation. The company&rsquo;s proprietary platform eGenesis Genome Engineering and Production (EGEN) platform leverages gene editing technologies to precisely edit genomes to tackle the risk of cross-species infection and graft rejection. It uses a multiplex gene editing approach that enables precise genetic modifications simultaneously.</div>

Reinventing gene therapies with next-generation technologies

Human Gene Editing

eGenesis

eGenesis Raises $191 Million for Human-Compatible Engineered Organs

<div>
 
 eGenesis specializes in gene editing for organ transplantation purposes. It develops human compatible (HuCo) organs and cells by using organs of other species (especially pigs) in a procedure called xenotransplantation. The company&rsquo;s proprietary platform eGenesis Genome Engineering and Production (EGEN) platform leverages gene editing technologies to precisely edit genomes to tackle the risk of cross-species infection and graft rejection. It uses a multiplex gene editing approach that enables precise genetic modifications simultaneously.
 
 
 As of January 2024, eGenesis had three programs in its pipeline, of which the most advanced program is a HuCo Liver Perfusion in its IND Enabling stage, whilst the others (HuCo heart and HuCo kidney ) were still in preclinical stages.
 
 
 Key customers and partnerships
 
 
 The company&rsquo;s partnerships include a research collaboration with the 
 <a href="https://www.globenewswire.com/news-release/2022/03/09/2399951/0/en/eGenesis-Announces-Research-Collaboration-with-the-University-of-Miami-to-Evaluate-Human-Compatible-Islet-Cells-in-Diabetes-Model.html">
 University of Miami
 </a>
 (March 2022) and 
 <a href="https://www.globenewswire.com/news-release/2020/11/05/2121081/0/en/eGenesis-Announces-Research-Collaboration-with-Leading-Academic-Medical-Center.html">
 Duke University 
 </a>
 School of Medicine (2020) to study gene-edited pancreatic islet cells.
 
 
 Funding and financials
 
 
 In its latest 
 <a href="https://www.globenewswire.com/news-release/2021/03/02/2185240/0/en/eGenesis-Announces-125-Million-Series-C-Financing.html">
 Series C
 </a>
 funding round in March 2021, eGenesis raised USD 125 million, bringing its total funds raised to USD 265 million. The funds were earmarked to advance its pipeline and further develop its gene editing platform. 
 
</div>

<div>
 
 Editas Medicine specializes in gene editing to develop novel therapeutics for a variety of areas including oncology, ocular diseases, and blood diseases. It leverages the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology, specifically Cas9 and Cas12a enzymes.&nbsp;
 
 
 The company develops both in vivo (gene editing done inside the body) and ex vivo (gene editing done in a specialized laboratory and returned to the body) therapeutics. As of March 2024, Editas has seven gene editing programs in its pipeline.&nbsp;
 
 
 One of the company&rsquo;s candidates was in the late clinical trial stages as of March 2024. The Phase I/II clinical trials on Editas&rsquo; in vivo gene editing therapy EDIT-101 have been ongoing since 2019 and the company announced that it had achieved proof of concept and identified a responder population in November 2022. For the first time ever (in April 2022), the company delivered its experimental in vivo CRISPR therapy to a 
 <a href="https://ir.editasmedicine.com/news-releases/news-release-details/editas-medicine-announces-dosing-first-pediatric-patient">
 pediatric patient
 </a>
 to treat Leber congenital amaurosis 10 (LCA10), an inherited early childhood eye disease. Its ex vivo gene editing therapy EDIT-301 holds two rare pediatric disease designations granted by the FDA for transfusion-dependent beta-thalassemia and sickle cell disease. The candidate also received 
 <a href="https://ir.editasmedicine.com/news-releases/news-release-details/editas-medicine-receives-fda-orphan-drug-designation-edit-301">
 orphan drug designation
 </a>
 in May 2022 for beta-thalassemia.
 
 
 Key customers and partnerships
 
 
 Founded in September 2013, Editas has secured several collaborations with other pharmaceutical and drug developers including 
 <a href="https://www.catalent.com/catalent-news/catalent-enters-into-strategic-partnership-with-editas-medicine-to-support-gene-editing-medicine-pipeline/">
 Catalent
 </a>
 (for therapy development and manufacturing support),
 <a href="https://ir.editasmedicine.com/news-releases/news-release-details/adverum-biotechnologies-and-editas-medicine-announce">
 Adverum Biotechnologies 
 </a>
 (to develop technologies to deliver gene editing medicines to the eye), 
 <a href="https://www.askbio.com/editas-medicine-and-askbio-enter-strategic-research-collaboration-to-explore-in-vivo-delivery-of-genome-editing-medicines-to-treat-neurological-diseases/">
 Asklepios BioPharmaceutical
 </a>
 (AskBio) (to research in vivo gene editing therapies for neurological diseases),
 <a href="https://ir.editasmedicine.com/news-releases/news-release-details/editas-medicine-and-bluerock-therapeutics-enter-strategic">
 BlueRock Therapeutics
 </a>
 (to develop medicines by combining cell therapy and gene editing technologies), and big pharma such as Bristol-Myers Squibb (to develop cell therapies for oncology).&nbsp;
 
 
 The company expanded its partnership with Azzur Cleanrooms on Demand (COD) in July 2023 with regard to continuing to manufacture Editas' candidate EDIT-301. 
 
 
 Funding and financials
 
 
 The company last raised funds in June 2023 when the company raised USD 125 million in a common stock offering. Editas Medicine did not disclose what the raised funds would be used for. The company has been listed on the Nasdaq since February 2016 and was the first CRISPR gene editing company to go public. 
 
</div>

Editas Medicine

<div>
 
 CRISPR Therapeutics specializes in developing gene editing-based novel therapeutics for a variety of areas including immuno-oncology and hemoglobinopathies. It leverages the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology, specifically Cas9 enzymes, and focuses predominantly on treating somatic cells that do not transfer DNA to the next generations, preventing future generations from contracting a genetic disease.&nbsp;
 
 
 The company develops both in vivo (gene editing done inside the body) and ex vivo (gene editing done in a specialized laboratory and returned to the body) therapeutics. As of March 2024, the company had 18 drug candidates in its pipeline. 
 
 
 In a milestone event in November 2023, the company&rsquo;s gene-editing therapy exagamglogene autotemcel, CASGEVY 
 <a href="https://sp-edge.com/updates/24093">
 (exa-cel)
 </a>
 , developed with Vertex Pharmaceuticals to treat sickle-cell disease and beta-thalassemia, received the world&rsquo;s first authorization from the UK's Medicines and Healthcare products, Regulatory Agency (MHRA). In December 2023, it received FDA approval for patients aged 12 and older. The drug for beta-thalassemia patients is also nearing its market entry in the US, with the FDA&rsquo;s decision expected on March 30, 2024.&nbsp;
 
 
 
 
 
 Key customers and partnerships
 
 
 
 
 The company has secured strategic collaborations with several companies to co-develop and co-commercialize gene editing medicines that include 
 <a href="https://investors.vrtx.com/news-releases/news-release-details/vertex-pharmaceuticals-and-crispr-therapeutics-amend">
 Vertex Pharmaceuticals
 </a>
 (2015) to develop a therapy (CTX001) for various indications including beta-thalassemia, sickle cell disease, and Duchenne muscular dystrophy; and 
 <a href="https://viacyte.com/press-releases/crispr-therapeutics-and-viacyte-announce-strategic-collaboration-to-develop-gene-edited-stem-cell-derived-therapy-for-diabetes/">
 ViaCyte
 </a>
 (September 2018) to develop VCTX210, a regenerative medicine for diabetes.
 
 
 Big pharma Bayer also signed an option agreement in 2019 with the company to co-develop and co-commercialize two candidates, after entirely handing over the joint venture Casebia Therapeutics to CRISPR.&nbsp;&nbsp;
 
 
 
 
 
 Funding and financials
 
 
 
 
 Founded in 2013, CRISPR has been listed on the Nasdaq since 2016. For 2021, the company reported a revenue of USD 913.1 million earned via milestone payments, collaborations, and licensing.
 
 
 
 
 
</div>

CRISPR Therapeutics

<div>
 
 Intellia Therapeutics specializes in gene editing to develop novel therapeutics for various areas, including immuno-oncology, autoimmune, and genetic diseases. It leverages the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology, specifically Cas9 enzymes.&nbsp;
 
 
 The company develops both in vivo (gene editing done inside the body) and ex vivo (gene editing done in a specialized laboratory and returned to the body) therapeutics. As of March 2024, it was working on 3 internal drug programs and four collaborative programs. As of March 2024, one program was in the late clinical stage, one program was in the early clinical stage, and five were in the research and preclinical stage. The company considers its lipid nanoparticle delivery system to be a key strength in minimizing genotoxicity risk and random insertion.
 
 
 Intellia acquired biotechnology company Rewrite Therapeutics for USD 45 million in February 2022 to leverage its gene editing and DNA-writing technologies. Intellia would also pay up to USD 155 million in additional milestone payments.
 
 
 
 
 
 Key customers and partnerships
 
 
 Intellia has partnered with a number of biotech and pharma companies, including: 
 1) Big pharma Novartis (January 2015), to research and co-develop CRISPR/Cas9-edited therapies to develop an ex-vivo treatment for sickle-cell disease and a number of undisclosed programs 
 2) Kyverna Therapeutics (January 2022), for the development of a next-generation CD19 CAR T-cell therapy for autoimmune diseases 
 3) ONK Therapeutics (February 2022), to develop engineered natural killer (NK) cell therapies for cancer treatment.&nbsp;
 
 
 In October 2023, the company expanded its research collaboration with 
 <a href="https://sp-edge.com/updates/22377">
 Regeneron Pharmaceuticals
 </a>
 (entered in April 2020) to develop gene-editing therapies for neurological and muscular diseases.
 
 
 
 
 
 Funding and financials
 
 
 Founded by Caribou Biosciences and Atlas Ventures in November 2014, Intellia has been listed on Nasdaq since May 2016. In 
 <a href="https://sp-edge.com/updates/15140">
 November 2022
 </a>
 , the company raised USD 300 million via an underwritten public offering&mdash;it did not disclose the purpose of the financing. For 2022, the company reported a revenue of ~USD 52&nbsp; million, earned through collaborations.
 
</div>

Intellia Therapeutics

<div>
 
 Based in the US and France, Cellectis develops off-the-shelf gene editing cancer immunotherapies based on allogeneic Chimeric Antigen Receptors T (CAR-T) cells dubbed UCARTs by leveraging the transcription activator-like effector nucleases (TALEN) technology.
 
 
 As of March 2024, the company had seven therapeutics in development; two targeting Leukemia, one for the treatment of non-Hodgkin lymphoma, one for Large B Cell Lymphoma, two for Multiple Myelnoma, and one for Renal Cell Carcinoma. Its Leukemia therapeutics were in Phase I of clinical trials, while its non-Hodgkin lymphoma solution was just entering Phase I of clinical trials. The company's therapeutics for Multiple Myeloma, another for Lymphoma, and Renal Cell Carcinoma, had been licensed out to other pharmaceutical companies.&nbsp;
 
 
 
 
 Key customers and partnerships
 
 
 In 
 <a href="https://sp-edge.com/updates/23389">
 November 2023
 </a>
 , Cellectis entered into a partnership with AstraZeneca to accelerate the development of gene editing therapeutics, with a focus on oncology, immunology, and rare diseases.&nbsp;
 
 
 Cellectis also partnered with Primera in January 2023 to develop in-vivo gene therapies for mitochondrial disease. Through the partnership, both entities would collaborate to genetically edit mutations in mitochondrial DNA and develop an engineering toolbox that can be used to develop therapeutics for mitochondrial diseases. 
 
 
 
 
 
 
 Funding and financials
 
 
 The company entered into several strategic collaboration agreements with AstraZeneca in November 2023. These agreements included an investment agreement relating to an initial equity investment of USD 80 million by subscribing for 16 million ordinary shares. Cellectis stated that it planned to use the proceeds received to develop gene editing tools, for research and development expenses incurred in developing its programs, and other general corporate purposes.
 
 
 
</div>

Cellectis

Caribou Biosciences specializes in gene editing to develop novel therapeutics for hematologic oncology indications using the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology. It develops allogeneic off-the-shelf gene edited therapies based on Chimeric Antigen Receptors T (CAR-T) cells and CAR Natural Killer (CAR-NK) cells.The company leverages its proprietary platform CRISPR hybrid RNA-DNA (chRDNA), which uses hybrid guides—both ribonucleic acid (RNA) and DNA nucleotides—to edit DNA. As of March 2024, Caribou had four candidates in its clinical pipeline, of which its lead candidate CB-010, a CAR-T therapy to treat relapsed/refractory B cell non-Hodgkin lymphoma, was in the Phase I clinical trial stage (March 2024). Its other CAR-T candidates, CB-011 for the treatment of relapsed/refractory Multiple Myeloma and CB-012, for the treatment of relapsed/refractory Acute Myeloid Leukemia, were also in Phase I of clinical trials. Its alternate application for CB-010 to treat autoimmune diseases was still in the discovery stage.The company intended to extend ex vivo (gene editing done in a specialized laboratory and returned to the body) therapies toward other indications outside oncology and implement its Cas12a chRDNA platform in in vivo (gene editing done inside the body) applications.Key customers and partnershipsThe company entered into a partnership with big pharma company <a href="https://news.abbvie.com/news/press-releases/abbvie-and-caribou-biosciences-announce-collaboration-and-license-agreement-for-car-t-cell-products.htm">Abbvie </a>in February 2021 for licensing and co-development of two CAR-T therapies. Caribou also entered into licensing agreements with <a href="https://www.businesswire.com/news/home/20201118005128/en/Caribou-Biosciences-Announces-Licensing-Agreement-for-scFvs-Targeting-CD371-to-Enable-Development-of-Allogeneic-Cell-Therapies">Memorial Sloan Kettering Cancer Center </a>(MSKCC) (November 2020), Corteva Agriscience, and Intellia Therapeutics. It also has a sales and assignment agreement with ProMab Biotechnologies Inc. (February 2020).Funding and financialsCaribou Biosciences went public on the Nasdaq Global Select Market in July 2021 and raised USD 304 million. The IPO proceeds were earmarked to fuel the company’s clinical development. For 2021, it recorded revenue of USD 9.6 million earned through licensing and collaborations.The company last raised funding in July 2023, when it raised USD 125 million in an upsized underwritten public offering. Caribou did not disclose what the funds would be used for.

Caribou Biosciences

Companies that develop novel therapeutics based on the CRISPR/Cas9 gene-editing technology

Companies that develop novel therapeutics based on other types of gene editing technologies including TALEN and ZFN

Companies that develop systems that enable the diagnosis of gene-edited therapies. Also includes systems that deliver gene-editing components into the human body

Companies that offer their gene-editing platforms to other pharma companies to develop therapeutics

Companies that offer support services to gene-editing companies, which include genomic research companies, gene-editing component manufacturing, and designing tools

Startups in the hub develop gene-editing treatments to cater to specific patients and patient profiles

Genomics enables precise changes in the DNA sequence of living organisms to develop treatments

ANALYST_QUICK_TAKE

<div>

 eGenesis, a biotechnology firm, has secured USD 191 million in a Series D funding round. The round was led by Lux Capital and included contributions from existing investors such as ARCH Ventures, Khosla Ventures, and Fresenius Medical Care Ventures, along with new investors like DaVita and Eisai Innovation.
 The funds will be used to further the development of the company's main product, EGEN-2784, aiming for its first study in human for kidney transplantation. A portion of the raised capital will also be allocated towards pipeline initiatives and improving production capabilities.
 The primary product of eGenesis, EGEN-2784, is a human-compatible pig kidney that has been genetically engineered. It involves three types of edits: the deletion of three genes related to hyperacute rejection, the addition of seven human transgenes to regulate rejection pathways, and the neutralizing of inherent retroviruses in the pig genome.

</div> Analyst QuickTake: 
 In <a href="https: 
//egenesisbio.com/press-releases/egenesis-announces-worlds-first-successful-transplant-of-genetically-engineered-porcine-kidney-in-a-living-patient/"> March 2024 </a> , eGenesis completed the world’s first successful xenotransplantation of a genetically modified pig kidney into a living patient. The transplant was authorized by the US FDA under the Expanded Access pathway and was performed at the Massachusetts General Hospital on a patient suffering from end-stage renal failure. The recipient passed away in May 2024, although the cause of death was deemed unrelated to the surgery.

eGenesis

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless